JP2010536857A - エリスロポエチン受容体ペプチドの製剤及び使用 - Google Patents

エリスロポエチン受容体ペプチドの製剤及び使用 Download PDF

Info

Publication number
JP2010536857A
JP2010536857A JP2010521912A JP2010521912A JP2010536857A JP 2010536857 A JP2010536857 A JP 2010536857A JP 2010521912 A JP2010521912 A JP 2010521912A JP 2010521912 A JP2010521912 A JP 2010521912A JP 2010536857 A JP2010536857 A JP 2010536857A
Authority
JP
Japan
Prior art keywords
peptide
peg
moiety
epo
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010521912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536857A5 (enExample
Inventor
ステッド，リチャード
ダリエジ，アン−マリー
チュン レオン，ロバート，ホン
イワシタ，ジュリア
ラング，ウィリアム
ウェインバーグ，マーク，エイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2010536857A publication Critical patent/JP2010536857A/ja
Publication of JP2010536857A5 publication Critical patent/JP2010536857A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2010521912A 2007-08-22 2008-07-23 エリスロポエチン受容体ペプチドの製剤及び使用 Pending JP2010536857A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95739607P 2007-08-22 2007-08-22
US98975807P 2007-11-21 2007-11-21
PCT/US2008/070926 WO2009025957A1 (en) 2007-08-22 2008-07-23 Erythropoietin receptor peptide formulations and uses

Publications (2)

Publication Number Publication Date
JP2010536857A true JP2010536857A (ja) 2010-12-02
JP2010536857A5 JP2010536857A5 (enExample) 2011-07-21

Family

ID=40194013

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010521912A Pending JP2010536857A (ja) 2007-08-22 2008-07-23 エリスロポエチン受容体ペプチドの製剤及び使用
JP2010521913A Pending JP2010536858A (ja) 2007-08-22 2008-07-23 エリスロポエチン受容体ペプチド製剤及び用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010521913A Pending JP2010536858A (ja) 2007-08-22 2008-07-23 エリスロポエチン受容体ペプチド製剤及び用途

Country Status (3)

Country Link
EP (1) EP2195002A4 (enExample)
JP (2) JP2010536857A (enExample)
WO (2) WO2009025957A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2709648A4 (en) * 2011-05-19 2015-04-08 Geysen Hendrik M COMPOUNDS FOR BINDING TO THE ERYTHROPOIETIN RECEPTOR
WO2015183545A1 (en) * 2014-05-28 2015-12-03 The Board Of Regents Of The University Of Texas System Novel compounds supports hematopoietic stem cells and red blood cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101606A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006133144A2 (en) * 2005-06-03 2006-12-14 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
WO2006136821A1 (en) * 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1625156T3 (pl) * 2003-05-12 2013-03-29 Affymax Inc Peptydy wiążące się do receptora erytropoetyny
US7919461B2 (en) * 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101606A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006133144A2 (en) * 2005-06-03 2006-12-14 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
WO2006136821A1 (en) * 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013022211; 医療ジャーナル　増刊号「新薬展望２００６」，　２００６，　Ｖｏｌ．４２，　ｐｐ．４２４-４３０ *
JPN6013022213; Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｈｅｍａｔｏｌｏｇｙ，　２００６，　Ｖｏｌ．３４，　ｐｐ．１３０３-１３１１ *
JPN6013022215; Ｊ．　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　ａｎｄ　Ｂｉｏｍｅｄｉｃａｌ　Ａｎａｌｙｓｉｓ，　２０１２，　Ｖｏｌ．７０，　ｐｐ．５１２-５１７ *

Also Published As

Publication number Publication date
WO2009025957A1 (en) 2009-02-26
JP2010536858A (ja) 2010-12-02
EP2195002A4 (en) 2011-09-07
WO2009025958A1 (en) 2009-02-26
EP2195002A1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
JP4949844B2 (ja) エリスロポエチン受容体に結合する新規ペプチド
JP4266028B2 (ja) エリスロポエチン受容体に結合する新規ペプチド
US20130012685A1 (en) Novel peptides that bind to the erythropoietin receptor
JP2013173763A (ja) エリスロポエチンレセプターペプチドの処方および使用
US20090221510A1 (en) Erythropoietin receptor peptide formulations and uses
US20120157660A1 (en) Novel peptides that bind to the erythropoietin receptor
US20130079283A1 (en) Erythropoitein Receptor Peptide Formulations and Uses
WO2009025957A1 (en) Erythropoietin receptor peptide formulations and uses
JP2009191056A (ja) 合成ペプチドをベースとするｅｐｏレセプターアゴニストを用いた抗エリスロポエチン抗体に媒介された障害の治療
HK1088906B (en) Peptides that bind to the erythropoietin receptor
HK1088616B (en) Novel peptides that bind to the erythropoietin receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130514

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131015